B
BIONTECH STORE
BioNTech was founded in 2008. This company provides the researching and manufacturing of pharmaceuticals. Their headquarters are located in Rheinland-Pfalz, Germany.
Country/Area ：South Korea
Company Email ：hr@biontech.com
Industry ：HealthcarePharmaceuticals
Company address ：12 An Der Goldgrube, Mainz, Rheinland-Pfalz, 55131, Germany
Company website ：*****
Company phone ：+49 49613190840
Established ：2008
Company Revenue ：$24,581,118,000
Number of employees ：3082
SIC Code ：87873
NAICS Code ：54541
Company News
BioNTech SE (BNTX) Q3 2023 Earnings Call Transcript
Nov 6, 2023
BioNTech SE (NASDAQ:NASDAQ:BNTX) Q3 2023 Earnings Call Transcript November 8, 2023 8:00 AM ETCompany ParticipantsVictoria Meissner - VP, Strategy &...
Nov 6, 2023
BioNTech Stock Jumps On Surprise Profit, Sales BeatNov 6, 2023
BioNTech unexpectedly reported a third-quarter profit and better-than-expected sales on Monday, pushing BNTX stock higher.
Nov 6, 2023BioNTech Earnings Beat. Pfizer’s Vaccine Partner Battles Covid Downturn.Nov 6, 2023
BioNTech stock has dropped 36% this year as demand fell for its Covid-19 vaccines produced with Pfizer.
Nov 6, 2023Biotheus Enters Into Strategic Partnership with BioNTech to Develop and Commercialize Bispecific Antibody Candidate Targeting PD-L1 and VEGF in Multiple Solid Tumor IndicationsNov 6, 2023
Bispecific Antibody Candidate PM8002 demonstrated encouraging data at this year's ASCO Annual Meeting (abstract #2536 & #e13091) and ESMO Congress (abstract #1992P) BioNTech will hold exclusive licenses to develop and commercialize PM8002 globally excluding Greater China ZHUHAI, China, Nov. 6, 2023 /PRNewswire/ -- Biotheus Inc. ("Biotheus"), a clinical-stage biotech company dedicated to the discovery and development of biologics for oncology and inflammatory diseases, today announced that the co
Nov 6, 2023BioNTech Announces Third Quarter 2023 Financial Results and Corporate UpdateNov 6, 2023
Conference call and webcast scheduled for November 6, 2023, at 8:00 am ET (2:00 pm CET)
Nov 6, 2023Web Summary
Q1: What is the company name and its main aim?
A1: The company name is BioNTech, and its main aim is to translate science into survival by developing new immunotherapies to contribute to improving the health of people worldwide.
Q2: In which industry does BioNTech operate?
A2: BioNTech operates in the biotechnology sector, specifically as a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases, and other serious diseases.
Q3: What is the company's vision and mission?
A3: BioNTech's vision is to improve the health of people worldwide, and its mission is to translate science into survival by developing new immunotherapies. The company's core values are innovation, passion, and unity, which form the basis of everything it does.
Q4: What are some of the diseases that BioNTech is working on treating?
A4: BioNTech is working on treating cancer, infectious diseases such as tuberculosis, malaria, human immunodeficiency virus (HIV), and other serious diseases with epidemic or pandemic potential, including mpox.
Q5: How does BioNTech contribute to the United Nations' Sustainable Development Goals (SDGs)?
A5: BioNTech contributes to SDG 3, which aims to ensure healthy lives and promote well-being for all people at all ages. The company is particularly focused on targets 3.3 (Combat infectious diseases) and 3b (Access to healthcare).
Q6: What rating agency has awarded BioNTech with the "Prime" status?
A6: BioNTech was awarded "Prime" status by the internationally recognized rating agency ISS ESG in 2024, placing it in the top 10% of all companies rated in the Pharmaceuticals and Biotechnology sector.
Q7: How does BioNTech measure its corporate social responsibility (CSR)?
A7: BioNTech measures its CSR through various means, including its Management Board, which is responsible for setting sustainability targets. The company also has a CSR Steering Board that supports the Board of Management in strategic matters.
Q8: What rating did BioNTech receive from Morningstar Sustainalytics?
A8: BioNTech received an overall rating of 25.9 on a scale up to 40+, category ‘Medium Risk’ out of a total of five risk categories, as of October 2024.
A1: The company name is BioNTech, and its main aim is to translate science into survival by developing new immunotherapies to contribute to improving the health of people worldwide.
Q2: In which industry does BioNTech operate?
A2: BioNTech operates in the biotechnology sector, specifically as a global next-generation immunotherapy company pioneering novel medicines against cancer, infectious diseases, and other serious diseases.
Q3: What is the company's vision and mission?
A3: BioNTech's vision is to improve the health of people worldwide, and its mission is to translate science into survival by developing new immunotherapies. The company's core values are innovation, passion, and unity, which form the basis of everything it does.
Q4: What are some of the diseases that BioNTech is working on treating?
A4: BioNTech is working on treating cancer, infectious diseases such as tuberculosis, malaria, human immunodeficiency virus (HIV), and other serious diseases with epidemic or pandemic potential, including mpox.
Q5: How does BioNTech contribute to the United Nations' Sustainable Development Goals (SDGs)?
A5: BioNTech contributes to SDG 3, which aims to ensure healthy lives and promote well-being for all people at all ages. The company is particularly focused on targets 3.3 (Combat infectious diseases) and 3b (Access to healthcare).
Q6: What rating agency has awarded BioNTech with the "Prime" status?
A6: BioNTech was awarded "Prime" status by the internationally recognized rating agency ISS ESG in 2024, placing it in the top 10% of all companies rated in the Pharmaceuticals and Biotechnology sector.
Q7: How does BioNTech measure its corporate social responsibility (CSR)?
A7: BioNTech measures its CSR through various means, including its Management Board, which is responsible for setting sustainability targets. The company also has a CSR Steering Board that supports the Board of Management in strategic matters.
Q8: What rating did BioNTech receive from Morningstar Sustainalytics?
A8: BioNTech received an overall rating of 25.9 on a scale up to 40+, category ‘Medium Risk’ out of a total of five risk categories, as of October 2024.
Customs Data
As a purchaser
As a Supplier
Get the Whole details
Contact
Total found ??? Contacts
All
Boss
Management
Procurement
Other
Get the Whole details
